Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes

References

• Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, Teramura T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308–316.
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B. (2000). Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131–1152.
   PubMed Web of Science ®Google Scholar
• Cai X, Wang RW, Edom RW, Evans DC, Shou M, Rodrigues AD, Liu W, Dean DC, Baillie TA. (2004). Validation of (-)-N-3-benzyl-phenobarbital as a selective inhibitor of CYP2C19 in human liver microsomes. Drug Metab Dispos 32:584–586.
   PubMed Web of Science ®Google Scholar
• Emoto C, Yamazaki H, Yamasaki S, Shimada N, Nakajima M, Yokoi T. (2000). Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes. Xenobiotica 30:943–953.
   PubMed Web of Science ®Google Scholar
• Emoto C, Yamazaki H, Iketaki H, Yamasaki S, Satoh T, Shimizu R, Suzuki S, Shimada N, Nakajima M, Yokoi T. (2001). Cooperativity of alpha-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 31:265–275.
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Sawada Y, Iwasaki K. (2005). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20:351–357.
   PubMedGoogle Scholar
• Emoto C, Iwasaki K. (2007). Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes. Xenobiotica 37:986–999.
   PubMed Web of Science ®Google Scholar
• Emoto C, Iwasaki K, Koizumi R, Utoh M, Murayama N, Uno Y, Yamazaki H. (2011). Species difference between cynomolgus monkeys and humans on cytochromes P450 2D and 3A-dependent drug oxidation activities in liver microsomes. J Health Sci 57:164–170.
   Google Scholar
• Galetin A, Houston JB. (2006). Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220–1229.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1991). Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 266:10019–10022.
   PubMed Web of Science ®Google Scholar
• Hickman D, Wang JP, Wang Y, Unadkat JD. (1998). Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207–215.
   PubMed Web of Science ®Google Scholar
• Houston JB, Kenworthy KE. (2000). In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246–254.
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Uno Y. (2009). Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 39:578–581.
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Murayama N, Koizumi R, Uno Y, Yamazaki H. (2010). Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet 25:388–391.
   PubMed Web of Science ®Google Scholar
• Komura H, Yasuda M, Yoshida NH, Sugiyama Y. (2002). Species difference in nisoldipine oxidation activity in the small intestine. Drug Metab Pharmacokinet 17:427–436.
   PubMedGoogle Scholar
• Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, Baillie TA. (2002). Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 303:969–978.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Trager WF. (1993). Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649–656.
   PubMed Web of Science ®Google Scholar
• Lin T, Pan K, Mordenti J, Pan L. (2007). In vitro assessment of cytochrome P450 inhibition: strategies for increasing LC/MS-based assay throughput using a one-point IC(50) method and multiplexing high-performance liquid chromatography. J Pharm Sci 96:2485–2493.
   PubMedGoogle Scholar
• Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, Lawton MP. (1999). Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Arch Biochem Biophys 372:189–196.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Matsushita A, Matsuno K, Iwasaki K, Utoh M, Nakamura C, Uno Y. (2010). Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab Pharmacokinet 25:290–297.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Koeda A, Morikawa H, Satoh T, Narimatsu S, Naito S. (2009). Tissue-specific mRNA expression profiles of drug-metabolizing enzymes and transporters in the cynomolgus monkey. Drug Metab Pharmacokinet 24:139–144.
   PubMed Web of Science ®Google Scholar
• Obach RS, Zhang QY, Dunbar D, Kaminsky LS. (2001). Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 29:347–352.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–255.
   PubMed Web of Science ®Google Scholar
• Ogasawara A, Kume T, Kazama E. (2007). Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410–418.
   PubMed Web of Science ®Google Scholar
• Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. (1996). First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14–24.
   PubMed Web of Science ®Google Scholar
• Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. (2006). The human intestinal cytochrome P450 “pie”. Drug Metab Dispos 34:880–886.
   PubMed Web of Science ®Google Scholar
• Patki KC, Von Moltke LL, Greenblatt DJ. (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938–944.
   PubMed Web of Science ®Google Scholar
• Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39:99–112.
   PubMed Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Binkley SN, Vandenbranden M, Wrighton SA. (1996). In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 41:181–186.
   PubMed Web of Science ®Google Scholar
• Sakuda S, Akabane T, Teramura T. (2006). Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans. Xenobiotica 36:331–340.
   PubMed Web of Science ®Google Scholar
• Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA. (1995). Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23:1231–1241.
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423.
   PubMed Web of Science ®Google Scholar
• Shimada T, Tsumura F, Yamazaki H. (1999). Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274–1280.
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Juvonen R, Pelkonen O. (2001). In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 29:217–222.
   PubMed Web of Science ®Google Scholar
• Thummel KE, O’Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. (1996). Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491–502.
   PubMed Web of Science ®Google Scholar
• Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, Uno Y. (2011). Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654–661.
   PubMed Web of Science ®Google Scholar
• Uno Y, Fujino H, Kito G, Kamataki T, Nagata R. (2006). CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. Mol Pharmacol 70:477–486.
   PubMed Web of Science ®Google Scholar
• Uno Y, Kumano T, Kito G, Nagata R, Kamataki T, Fujino H. (2007). CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans. Xenobiotica 37:30–43.
   PubMed Web of Science ®Google Scholar
• Uno Y, Iwasaki K, Yamazaki H, Nelson DR. (2011a). Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346–361.
   PubMed Web of Science ®Google Scholar
• Uno Y, Matsuno K, Murayama N, Nakamura C, Yamazaki H. (2011b). Metabolism of P450 probe substrates by cynomolgus monkey CYP2C76. Basic Clin Pharmacol Toxicol 109:315–318.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2004). Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647–660.
   PubMed Web of Science ®Google Scholar
• Walsky RL, Obach RS. (2007). A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1′,1′-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab Dispos 35:2053–2059.
   PubMed Web of Science ®Google Scholar
• Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. (1987). Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029–1036.
   PubMed Web of Science ®Google Scholar
• Wattanachai N, Polasek TM, Heath TM, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, Miners JO. (2011). In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6a-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815–824.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221.
   PubMed Web of Science ®Google Scholar
• Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201–1208.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Turvy CG, Guengerich FP, Shimada T. (1997). Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 25:168–174.
   PubMed Web of Science ®Google Scholar